Moderna announced on Wednesday that its COVID-19 vaccine decreases in efficacy after a year, suggesting a potential benefit in having a booster shot of its mRNA vaccine. New clinical trial data showed that breakthrough COVID-19 infections are less common among people who received Moderna’s vaccine, mRNA-1273, more recently compared to less recently, the company said in a release. The company was relaying findings from a data analysis of over 14,000 people at median eight months after their first dose and over 11,000 people at median 13 months after their first dose. The study is awaiting peer review. Researchers found that in July-August, around the time when the Delta strain of the CCP (Chinese Communist Party) virus was regarded as the predominant strain, there were 88 CCP virus breakthrough cases in the cohort vaccinated more recently (49.0 cases per 1,000 person-years) compared with 162 cases among the cohort vaccinated earlier (77.1 cases per 1,000 …